Skip to main content

Table 1 Therapeutic approaches for breast malignancies in clinical trials in subjects with BRCA1 and BRCA2 mutations. Tables and data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)

From: Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

Conditions (Title)

Interventions of clinical trial

Study type

Study completion

Metastatic breast cancer

• Drug: Placebo, veliparib, and carboplatin

Interventional, phase 2

2019

 • BRCA1 and BRCA2 mutation carrier with BC

 • Hereditary BC/OC with BRCA1 and BRCA2

• Drug: Letrozole, and placebo

Interventional, phase 3

2022

 • Recombinant hCG

 • BRCA1 and BRCA2 mutation in BC

• Drug: Ovitrelle, and recombinant Hcg

Interventional phase 4

2021

 • OC, BC, and prostate cancer

• Drug: Olaparib

Interventional, phase 2

2018

 • BRCA1 and BRCA2 mutation carrier

 • BC and metastatic BC, and OC

• Drug: Rucaparib (CO-338; AG-014699 or PF-01367338)

• Expression evaluation

Interventional, phase 2

2015

 • BC metastatic

 • BRCA1 and BRCA2 mutation carrier

• Drug: Olaparib therapy, and chemotherapy with doctor’s choice

Interventional, phase 3

2019

 • BRCA1 and BRCA2 mutation carrier in BC

• Biological: Therapeutic estradiol

• Drug: Deslorelin, therapeutic testosterone

• Deslorelin combined with low-dose add-back estradiol and testosterone

Interventional, phase 2

2019

 • BRCA1 and BRCA2 mutation carrier in BC

• Supplement: S0812: cholecalciferol supplementation

Interventional, not applicable

2017

 • BC

 • Metastatic BC

 • BRCA1 and BRCA2 mutation

• Drug: ABT-888 and temozolomide

Interventional, phase 2

2020

 • Human EGF2 negative carcinoma of breast

 • BRCA1 and BRCA2 mutation

• Drug: Niraparib as neoadjuvant therapy

Interventional, phase 1

2020

 • Breast neoplasms

• Drug: Dexamethasone, trabectedin

Interventional, phase 2

2011

 • Breast malignancy

 • BRCA1 and BRCA2 mutation carrier

• Drug: Talazoparib (BMN 673)

Interventional, phase 2

2018

 • Breast neoplasms

 • BRCA1 and BRCA2 mutation carrier

• Drug: Talazoparib (BMN 673): a PARP inhibitor

• Drug: Physician’s choice

Interventional, phase 3

2019

 • Advanced BC

 • HER2/Neu negative

 • TNBC

• Drug: Talazoparib Tosylate

Interventional, phase 2

2019

 • BC: Stage IV

 • OC

 • BRCA1 and BRCA2 mutation

• Drug: Carboplatin, eribulin, and veliparib

Interventional, phase 2

2020

 • Basal-like breast carcinoma

 • BRCA1 and BRCA2 mutation

• Drug: Veliparib

• Laboratory evaluation and biomarker assessment

Interventional, phase 1

2017

 • Atypical ductal breast hyperplasia

 • BRCA1 and BRCA2 mutation carrier

• Metformin hydrochloride as drug

• Placebo

Interventional, phase 3

 

 • Atypical ductal breast hyperplasia

 • BRCA1 and BRCA2 mutation

• Dietary supplement: curcumin

• Biomarker evaluation

Interventional, not applicable

2019